{"id":"W2907026589","doi":"10.1055/s-0038-1675816","title":"The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations","year":2018,"lang":"en","type":"review","venue":"Thrombosis and Haemostasis","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute; McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Hamilton Health Sciences Foundation; National Institute for Health and Care Research; McMaster University; Hamilton Health Sciences; Heart and Stroke Foundation of Canada","keywords":"Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Medicine; Vitamin K antagonist; Warfarin; Direct thrombin inhibitor; Intensive care medicine; Clinical trial; Stroke (engine); Dosing; Anticoagulant; Atrial fibrillation; Pharmacology; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004274156,0.0003213859,0.001304271,0.000210044,0.0004844488,0.0001618809,0.00009492812,0.0001620563,0.0001152625],"category_scores_gemma":[0.00009492468,0.0002108001,0.0003349086,0.0004672942,0.0001916505,0.00009833485,0.0001058666,0.0001937641,0.0000884429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001098177,"about_ca_system_score_gemma":0.0001508303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005714705,"about_ca_topic_score_gemma":0.0001355487,"domain_scores_codex":[0.9983143,0.0001281027,0.0005773077,0.0003912344,0.0002919307,0.0002971431],"domain_scores_gemma":[0.9990263,0.0002075546,0.0001962407,0.0003727592,0.00005726503,0.0001398886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001129718,0.00004839857,0.01171634,0.003769992,0.0005068664,0.00001006005,0.0001502779,2.712901e-7,0.000001419261,0.0004728692,0.07425477,0.9089558],"study_design_scores_gemma":[0.0005547931,0.00006009069,0.04773866,0.00202512,0.001324034,0.000004914692,0.000052303,0.00001529927,7.30584e-7,0.00007098554,0.9479324,0.0002206741],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001654991,0.9875484,0.00003153152,0.00522239,0.001597235,0.002532801,0.0001288953,0.00006808905,0.001215641],"genre_scores_gemma":[0.0005168389,0.9941044,0.0001334939,0.0001044214,0.003985475,0.00001958101,0.0002731523,0.00003998745,0.000822644],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9087351,"threshold_uncertainty_score":0.859618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1929602971005452,"score_gpt":0.4305789342408461,"score_spread":0.2376186371403009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}